DCF Valuation
China Medical & HealthCare Group Limited (COLRF) DCF Valuation — Is COLRF undervalued?
The estimated DCF fair value of one China Medical & HealthCare Group Limited (COLRF) share is $0.15. Compared to the current market price of $0.08, the stock is undervalued by 86.4%.
DCF fair value
$0.15
Market price
$0.08
Upside / downside
+86.4%
Prefer the inverse question? See what growth rate the market is pricing into COLRF →
China Medical & HealthCare Group Limited (COLRF) DCF valuation FAQ
What is the DCF fair value of China Medical & HealthCare Group Limited (COLRF)?
The discounted-cash-flow model estimates the intrinsic fair value of one China Medical & HealthCare Group Limited (COLRF) share at $0.15, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is China Medical & HealthCare Group Limited (COLRF) overvalued or undervalued?
Against the current market price of $0.08, the DCF fair value of $0.15 implies COLRF is undervalued by 86.4%.
How is the COLRF DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from China Medical & HealthCare Group Limited's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when China Medical & HealthCare Group Limited files a new quarterly or annual report.
How this COLRF valuation is built
The model projects ten years of China Medical & HealthCare Group Limited's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing China Medical & HealthCare Group Limited's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when China Medical & HealthCare Group Limited files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-07-27.